View in EDS HTML Full Text PDF Full Text

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Authors: Shivapurkar, Narayan1 (AUTHOR), Gay, Martha D.1 (AUTHOR), He, Aiwu2 (AUTHOR), Chen, Wenqiang1 (AUTHOR), Golnazar, Shermineh3 (AUTHOR), Cao, Hong1 (AUTHOR), Duka, Tetyana1 (AUTHOR), Kallakury, Bhaskar4 (AUTHOR), Vasudevan, Sona3 (AUTHOR), Smith, Jill P.1,2 (AUTHOR) jps261@georgetown.edu
Source: International Journal of Molecular Sciences. Feb2023, Vol. 24 Issue 4, p3625. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:16616596
DOI:10.3390/ijms24043625